Kura Oncology, Inc. (Nasdaq:KURA) announced on 5/2/18 that the U.S. Patent and Trademark Office (USPTO) has issued a new patent protecting the company's lead product candidate, tipifarnib. U.... read more
Kura Oncology, Inc. (Nasdaq:KURA) announced on 5/2/18 that the U.S. Patent and Trademark Office (USPTO) has issued a new patent protecting the company's lead product candidate, tipifarnib. U.... read more
Having recently completed a series A financing round of up to $40 million, Cirius Therapeutics announced on 5/2/2018 that it has reached its enrollment target in its Phase 2b EMMINENCE trial for... read more
Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has submitted an Investigational New... read more
Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative,... read more
NeoImmuneTech (NIT), an immunotherapy drug development company focused on advanced cancer treatments, and its parent company Genexine, have entered into an agreement with Roche to enable studies... read more
Colorectal cancer has a high mortality rate in advanced stages of the disease with few effective therapies. Researchers at the Sidney Kimmel Cancer Center (SKCC) at Jefferson Health show that a... read more
AbbVie (NYSE: ABBV), announced on 5/1/18 that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for risankizumab, an investigational interleukin-... read more
Medtronic plc (NYSE:MDT) announced on 5/1/18 that the U.S. Food and Drug Administration (FDA) has granted premarket approval for Medtronic's Deep Brain Stimulation (DBS) therapy as adjunctive... read more
Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases, announced long-term preclinical efficacy data... read more
On April 13, 2018 the 4th U.S. Circuit Court of Appeals struck down a Maryland law that allowed the state attorney general to sue drugmakers who raised prices on generic or off-patent drugs by... read more
Biogen (Nasdaq: BIIB) and Neurimmune announced today that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab... read more
Gilead Sciences, Inc. (Nasdaq: GILD) and Verily Life Sciences LLC, an Alphabet company, today announced a scientific collaboration using Verily’s Immunoscape platform to identify and better... read more
On April 19th an FDA advisory committee voted unanimously to recommend approval of the first prescription cannabidiol medicine — to treat rare and severe forms of epilepsy. The drug is known as... read more
A proposed $20 million settlement has been reached in a class action lawsuit involving the antibiotic drug Solodyn. The lawsuit claims that Medicis Pharmaceutical Corp., Impax Laboratories, Inc.,... read more
Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, announced on 4/30/18 the filing of an Investigational New Drug (IND) Application with... read more
NanOlogy LLC, a clinical-stage pharmaceutical development company, has completed the dose escalation phase of an open-label clinical trial of NanoPac (submicron particle paclitaxel (Taxol) sterile... read more
LCS Group, LLC (“LCS”) announced today that it has filed a federal lawsuit in the Southern District of New York against Shire Plc, Shire Development LLC, and Shire LLC (“Shire”) alleging Shire... read more
The “Creating and Restoring Equal Access To Equivalent Samples Act of 2017” or the “CREATES Act of 2017” is a bill in the Senate that is intended to expedite the development of generic... read more
UCB announced on 4/27/18 that the European Committee for Medicinal Products for Human Use (CHMP) has recommended approval of a label extension for Cimzia (certolizumab pegol), to include a new... read more
Eloxx Pharmaceuticals, Inc. (“Eloxx”), (NASDAQ:ELOX), announced on 4/27/18 that it has received orphan-drug designation from the Food and Drug Administration (FDA) for ELX-02 for treatment of... read more